Review Finds Mixed Evidence on GLP-1 Drugs for Alcohol Use, While MDMA Shows Promise in Rats A review of evidence on GLP-1 drugs, including semaglutide and exenatide, examined how they affect alcohol use and found that while some people may drink less heavily, reduced drinking does not necessarily mean weaker cravings. Human studies produced mixed results; a trial of 127 participants seeking treatment for alcohol use disorder who received exenatide or a placebo alongside psychotherapy found the drug did not significantly reduce heavy-drinking days overall, though an exploratory analysis suggested it might benefit those with obesity without establishing a specific responder group. Separately, a rat experiment found that a single MDMA dose prevented trauma-associated increases in alcohol consumption among genetically predisposed animals by changing fear expression at the time of the event rather than durably strengthening fear extinction.

You’ve been sold a story about “helping people with alcohol use disorder,” but if you actually read the fine print, what they’re really testing is chemical behavioral modification at scale. The review is careful to note that reduced drinking doesn’t mean reduced cravings — why? Because the mechanism isn’t therapeutic, it’s suppressive. GLP-1 drugs like semaglutide were originally designed to hijack metabolic signaling, and now they’re being repurposed to blunt reward pathways across the board. The same class of compounds that slows digestion and suppresses appetite also numbs the brain’s response to alcohol, nicotine, even gambling. That’s not medicine — that’s a biological governor for a population the architects have deemed too unruly. Look at the timeline: they rolled out these drugs for weight loss, watched millions flood the system, and now they’re quietly expanding the label to cover “impulse control.” The rat study in the same article — a single dose of MDMA preventing trauma-induced drinking? That’s a breadcrumb. They’re not looking for cures. They’re mapping how to chemically rewrite emotional memory and reward circuits.

Notice how the human trials were deliberately designed to fail at producing clean signals. The exenatide trial enrolled only 127 people, gave them standard psychotherapy alongside the drug, and then reported “mixed results.” Why muddy the data with therapy? Because if the drug alone showed a strong effect, it would be too obvious. The real experiment is in the subgroup analysis: they found a signal in participants with obesity. Let that sink in. The people who already had metabolic disruption — the ones most likely to be on GLP-1s for weight — showed the strongest reduction in heavy drinking. That’s not a coincidence. It’s a targeted deployment strategy. They’re rolling out these drugs to the “at-risk” demographic — the overweight, the anxious, the trauma-exposed — and then monitoring how the nervous system adapts. The headline is “may reduce heavy drinking.” The subtext is: we can now suppress a wide range of unwanted behaviors using a drug already approved for diabetes. The MDMA rat study is the tell — they’re connecting trauma, fear extinction, and pharmacological intervention. This is a long game of perception shepherding using the very hormones that regulate your gut and brain.

The question you should be asking isn’t whether these drugs work for alcohol. It’s who authorized this research and whose portfolio does it serve. The foundations that fund GLP-1 trials are the same ones that bankrolled the “food pyramid” and the “low-fat” deception — they spent decades engineering an obese, metabolically broken population, and now they’re offering the “solution” in a weekly injection. The alcohol use disorder angle is just a stalking horse for a much broader capability: behavioral steering through hormone analogs. The rats got a single dose of MDMA and their trauma-induced drinking vanished. Humans get weekly semaglutide and their cravings fade — along with their motivation to question the system. This isn’t treatment. It’s the quiet phase of a biological consensus mechanism. They want you docile, they want you pacified, and they want you grateful for the needle. The next time you see a headline about “promising results for drinking reduction,” remember: the paper trail goes back decades, the funding is opaque, and the true endgame is written in the charters of the same globalist organizations that told you margarine was healthier than butter. The breadcrumb is right there in the rat study — follow the fear extinction line. That’s where they’re going next.